Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cardiol to Advance CardiolRx into a Late-stage Trial in Recurrent Pericarditis
Details : CardiolRx (cannabidiol) is an oral solution that works by inhibiting activation of the NLRP3 inflammasome. It is being evaluated for recurrent pericarditis.
Product Name : CardiolRx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 22, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients
Details : CardiolRx (pure cannabidiol solution) which is a NLRP3 inflammasome inhibitor. It is being evaluated for the treatment of recurrent pericarditis.
Product Name : CardiolRx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 17, 2024
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CardiolRx™ (cannabidiol), is a oral solution formulation being developed for use in heart diseases. Cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the inflammation and fibrosis a...
Product Name : CardiolRx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 17, 2023
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CardiolRx (cannabidiol), is a pharmaceutically produced oral solution formulation that is being clinically developed for use in heart diseases and inhibits activation of the inflammasome pathway.
Product Name : CardiolRx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 12, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CardiolRx (cannabidiol), is a pharmaceutically produced oral solution formulation that is being clinically developed for use in heart diseases and inhibits activation of the inflammasome pathway.
Product Name : CardiolRx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 11, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CardiolRx (cannabidiol), is a pharmaceutically manufactured oral solution formulation that is being clinically developed for use in Recurrent Pericarditis and inhibits activation of the inflammasome pathway.
Product Name : CardiolRx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study results demonstrate the active pharmaceutical ingredient ("API") in CardiolRx™ (Cannabidiol) inhibits and also promotes the reversal of mechanisms known to play a role in the occurrence and development of fibrotic CVD.
Product Name : CardiolRx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 10, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CardiolRx (cannabidiol), is a pharmaceutically produced oral solution formulation that is being clinically developed for use in heart diseases and inhibits activation of the inflammasome pathway.
Product Name : CardiolRx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
March 08, 2022
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Topline results demonstrated that CardiolRx was safe and generally well tolerated at all dose levels, with no serious adverse events reported in the study.
Product Name : CardiolRx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 04, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CardiolRx (cannabidiol), is a pharmaceutically manufactured oral solution formulation that is being clinically developed for use in Acute Myocarditis and inhibits activation of the inflammasome pathway.
Product Name : CardiolRx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 25, 2021
Lead Product(s) : Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable